279 completed. 279 Phase 1, 55 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 279 | Completed 279 |
| Phase 2 | 55 | Completed 55 |
Follow Mood Disorders: new trials by email Literature Review of Mood Disorders trials Research Report on Mood Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective. Group A. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by anxiety disorders and depression., Group B. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by PTSD, Group C. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder. - Anxiety, Depression | Phase 1 | Completed | Rakitzi, Stavroula | 107 | 2025-06-02 | 2026-08-04 |
| Multiple Ascending Dose Phase 1 Study of ALA-3000 ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR - Treatment Resistant Depression | Phase 1 | Completed | Alar Pharmaceuticals Inc. | 37 | 2025-04-21 | 2025-12-31 |
| ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD) ENX-104, Placebo - Major Depressive Disorder | Phase 1 | Completed | Engrail Therapeutics INC | 48 | 2025-02-17 | 2025-12-31 |
| A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode SEP-380135, Placebo - Schizophrenia, Major Depressive Disorder (MDD) | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 43 | 2024-11-07 | 2026-04-24 |
| Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety BMND08, Brain electrical activity monitor, Pharmacokinetic Study of Sublingually Administered Psychoactive Substance - Healthy Volunteers | Phase 1 / Phase 2 | Completed | Biomind Labs Inc. | 40 | 2024-10-21 | 2025-03-05 |
| A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression SP-624, Placebo - Major Depressive Disorder, Depression | Phase 1 | Completed | Sirtsei Pharmaceuticals, Inc. | 26 | 2024-08-22 | 2026-05-28 |
| A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET LV232 40mg, Escitalopram 20 mg, LV232 60mg - Major Depressive Disorder | Phase 1 | Completed | Vigonvita Life Sciences | 20 | 2024-05-30 | 2025-06-10 |
| KET-RO Plus RO DBT for Treatment Resistant Depression Ketamine Infusion plus RO DBT - Treatment Resistant Depression | Phase 1 | Completed | Washington University School of Medicine | 16 | 2023-10-04 | 2026-03-30 |
| Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE 1) Ketamine (Ketalar) Dose Level 1, Ketamine (Ketalar) Dose Level 2, Ketamine (Ketalar) Dose Level 3 - Pain, Postoperative, Depression, Postpartum | Phase 1 | Completed | Grace Lim, MD, MS | 12 | 2023-09-25 | 2025-09-12 |
| A Study on the Safety, Pharmacokinetics, and Food Effects of MI078 Capsules MI078, Placebo - Postpartum Depression | Phase 1 | Completed | Nanjing Minova Pharmaceutical Co., Ltd. | 98 | 2023-09-09 | 2025-05-21 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD) ABBV-932, Placebo for ABBV-932 - Healthy Volunteers, Generalized Anxiety Disorder (GAD) | Phase 1 | Completed | AbbVie | 72 | 2023-08-31 | 2025-03-17 |
| Psilocybin-assisted CBT for Depression Psilocybin, Cognitive behavioral therapy - Major Depressive Disorder | Phase 1 | Completed | University of California, Los Angeles | 16 | 2023-06-27 | 2026-05-19 |
| A Study of BRII-297 in Healthy Adult Subjects BRII-297, Placebo - Postpartum Depression | Phase 1 | Completed | Brii Biosciences Limited | 41 | 2023-05-15 | 2024-01-18 |
| Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD) Zuranolone - Major Depressive Disorder | Phase 1 | Completed | Biogen | 19 | 2023-04-19 | 2025-03-26 |
| Assessing Dopamine Transporter Occupancy in the Healthy Adult Brain With Toludivenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Toludivenlafaxine hydrochloride sustained-release tablets - Major Depressive Disorder | Phase 1 | Completed | Shanghai Mental Health Center | 6 | 2023-03-02 | 2023-07-27 |
| An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the Brain MIJ821 - Major Depressive Disorder | Phase 1 | Completed | Novartis Pharmaceuticals | 10 | 2023-01-11 | 2024-04-01 |
| IM and IV SPL026 Drug Product in Healthy Participants SPL026 IV, SPL026 IM - Major Depressive Disorder | Phase 1 | Completed | Small Pharma Ltd | 14 | 2023-01-03 | 2024-03-22 |
| SPL026 With or Without SSRIs in Participants With MDD SPL026 - Major Depressive Disorder | Phase 1 | Completed | Small Pharma Ltd | 18 | 2022-12-13 | 2024-06-14 |
| Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers apimostinel, Placebo - Major Depressive Disorder | Phase 1 | Completed | Syndeio Biosciences, Inc | 40 | 2022-10-15 | 2023-04-11 |
| D-Cycloserine+iTBS PK Study D-cycloserine, Transcranial Magnetic Stimulator - Major Depressive Disorder | Phase 1 | Completed | University of Calgary | 12 | 2022-10-12 | 2023-09-11 |
Showing 20 of 279. Sign in to see all of them.
Depressive Disorder, Major (145) · Depression (61) · Bipolar Disorder (51) · Depressive Disorder (51) · Schizophrenia (34) · Anxiety Disorders (20) · Depressive Disorder, Treatment-Resistant (15) · Psychotic Disorders (12) · Stress Disorders, Post-Traumatic (10) · Substance-Related Disorders (9) · Mental Disorders (7) · Depression, Postpartum (6) · Dysthymic Disorder (6) · Alcoholism (5)
Mental Disorders (272) · Depressive Disorder (151) · Behavior (66) · Behavioral Symptoms (59) · Bipolar and Related Disorders (51) · Schizophrenia Spectrum and Other Psychotic Disorders (34) · Chemically-Induced Disorders (14) · Trauma and Stressor Related Disorders (12) · Pathological Conditions, Signs and Symptoms (10) · Nervous System Diseases (9) · Stress Disorders, Traumatic (8) · Female Urogenital Diseases and Pregnancy Complications (7) · Urogenital Diseases (7) · Neurologic Manifestations (6)
alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol (16) · Paliperidone Palmitate (14) · Ketamine (12) · Cognitive Behavioral Therapy (6) · Desvenlafaxine Succinate (6) · Escitalopram (6) · Therapeutics (6) · N-Methyl-3,4-methylenedioxyamphetamine (5) · Sertraline (5) · Bupropion (4) · Citalopram (4) · Duloxetine Hydrochloride (4) · Lithium (4) · Paroxetine (4) · Valproic Acid (4)
GlaxoSmithKline (29) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (24) · Eli Lilly and Company (19) · Luye Pharma Group Ltd. (9) · Janssen Research & Development, LLC (6) · National Institute of Mental Health (NIMH) (6) · New York State Psychiatric Institute (6) · University of California, Los Angeles (6) · University Hospital, Basel, Switzerland (5) · Mclean Hospital (4) · Otsuka Pharmaceutical Development & Commercialization, Inc. (4) · Biogen (3) · Butler Hospital (3) · Massachusetts General Hospital (3) · Medical University of South Carolina (3)
United States (137) · United Kingdom (23) · China (17) · Germany (15) · Canada (9) · Netherlands (9) · Australia (8) · Switzerland (5) · Belgium (4) · Brazil (4) · Japan (4) · India (3) · Israel (3) · Singapore (3) · Argentina (2)
Matthias E Liechti, MD (5) · Amy Sun, MD, PhD, MBA (2) · Catherine Harmer (2) · Diego A Pizzagalli, PhD (2) · Fabian Devlin, MD (2) · Ihsan M Salloum, MD, MPH (2)
PMID 22700038, PMID 29912955, PMID 31784354, PMID 32241310, PMID 35963959, PMID 16319710, PMID 16585452, PMID 16894061, PMID 17429407, PMID 18061147, PMID 18227146, PMID 18762591, PMID 18996507, PMID 19454920, PMID 19545857, PMID 19736358, PMID 19744406, PMID 19897179, PMID 19914605, PMID 19995444, PMID 20673547, PMID 20679587, PMID 20854181, PMID 21450159, PMID 21459988, PMID 21715530, PMID 21731830, PMID 21736514, PMID 22065593, PMID 22125120, PMID 22296967, PMID 22297150, PMID 22409700, PMID 22473055, PMID 22521148, PMID 22570264, PMID 22574166, PMID 22722512, PMID 22945620, PMID 23300127, PMID 23482332, PMID 23562618, PMID 23685546, PMID 23800483, PMID 23805231, PMID 23857311, PMID 23916389, PMID 23990896, PMID 24191345, PMID 24462229
2016 (3), 2017 (2), 2014 (1), 2015 (1), 2018 (1), 2019 (1), K01DA029645 (1), K01MH112876 (1), K23MH064528 (1), K23MH074860 (1), K24DA000435 (1), K24MH102743 (1), P20MH090318 (1), R01AA015385 (1), R01AA024933 (1)